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Purpose: Therapeutic strategies attacking oral squamous cell carcinoma have not essentially succeeded to improve
long-term prognosis and overall survival over the last decades. Therefore, in this study, we aimed to illuminate themolecular
regulation of angiogenesis in this tumour entity in order to demask novel markers of prognosis or therapeutic approach.
Materials and methods: A panel of significant transcriptional alterations in angiogenic genes of 83 cancer samples was
established by comparison to 30 samples of healthy oral mucosa with microarray technique. Immunohistochemistry
(IHC) was performed to trace the signalling cascade from gene to protein level.
Results: A distinctive expression profile of VEGFA, EFNB2, PECAM1/CD31, ANGPT1 and ANGPT2 was revealed: VEGFA,
EFNB2, and ANGPT2 were found overexpressed in 84 % to 95 % of tumour samples. In contrast, the expression of CD31
and ANGPT1 was downregulated in 80 % to 95 % of tumour samples. IHC confirmed results of the microarray analysis.
Tumours with lymphatic spread showed higher gene expression rates of VEGFA, EFNB2 and ANGPT2 in moderately
differentiated tumours and of VEGFA and EFNB2 in small tumours, respectively. The ANGPT1/ ANGPT2 transcription ratio
was found decreased in larger tumours and especially in tumours without lymphatic spread.
Conclusions: A characteristic expression profile of angiogenic markers was established. The specific overexpression of
EFNB2 in small tumours with lymphatic spread and the typical decrease of the ANGPT1/ ANGPT2 ratio in larger tumours
give weight to EFNB2 and angiopoietins as prognostic factors and potential therapeutic targets.
Keywords: Oral squamous cell carcinoma, Microarray analysis, Angiopoietins, VEGF, EFNB2, AngiogenesisIntroduction
Oral squamous cell carcinoma (OSCC) is one of the most
commonly diagnosed cancer entities in the world and is
associated with unchanged high morbidity and mortality.
Nearly 500 000 cases are diagnosed every year, and over
250 000 patients find death due to the disease [1, 2].
Tracing current experimental and clinical results,
growth and progression of the disease are closely related
to a functioning vascularisation. As in other malignant
tumours, an increasing vascularity, from healthy mucosa
over dysplastic lesion to invasive carcinoma has been ob-
served [3, 4]. With regard to this, different angiogenic
effects are exerted by the vascular endothelial growth* Correspondence: Sonja.Sielker@ukmuenster.de
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creativecommons.org/publicdomain/zero/1.0/factor (VEGF). It promotes endothelial cell growth as
well as proliferation and it induces vascular permeability
allowing for cell migration. Analysis of VEGF gene ex-
pression in OSCC revealed an obvious up-regulation of
the mitogen in the majority of studied tumour samples
which correlated with tumour size [5].
Kaemmerer et al. were able to show that higher micro-
vessel density was associated not only with higher
tumour stage as well as earlier relapse, but also with a
higher rate of metastasis and significantly decreased
overall and disease-free survival [6]. These findings pro-
vide the base for and strongly suggest further elucidation
of VEGF expression and regulation in malignant tissues.
As a further factor, Angiopoietin 1 (ANGPT1) plays a
significant role in endothelial cell survival and vascular
maturation. Its molecular action leads to a tightening
of cell junctions and reduces cell permeability andcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Jung et al. Head & Face Medicine  (2015) 11:19 Page 2 of 8inflammatory response. In colorectal cancer, reverse ef-
fects of ANGPT1 have been detected: ANGPT1 overex-
pression in combination with VEGF seems to induce
angiogenesis whereas ANGPT1 alone seems to exert an
anti-angiogenic effect by stabilizing the existing vascula-
ture, and thus reducing any remodelling effects [7].
Abnormal levels of ANGPT1 and Angiopoietin 2
(ANGPT2), together with their receptor, have been
observed in prostate and breast cancer [8].
ANGPT2, in general, acts as ANGPT1-Tie antagonist
and exerts anti-angiogenic effects in several tumour en-
tities. In OSCC, ANGPT2 overexpression comes along
with increased malignancy and poor prognosis [9]. In
other cases, ANGPT2 signalling is able to induce blood
vessel degradation and endothelial cell sensitization fol-
lowing the impact of angiogenic cytokines such as
VEGF; moreover, ANGPT2 induces apoptosis in endo-
thelial cells in the absence of VEGF. ANGPT2, as well as
VEGF are ligands for a receptor specific tyrosine kinase
that is expressed on endothelial cells (ECs), exclusively.
This ligand-receptor interaction results in vessel matur-
ation and growth [9]. In addition, ANGPT2 plays a signifi-
cant role during early stages of the angiogenic switch in the
formation of tumours when it induces apoptosis in endo-
thelial cells; this results in massive hypoxia in the con-
cerned tumour tissue. As a consequence, overexpression of
VEGF and the reestablishment of a viable vasculature arises
[10]. The synergistic effect of VEGF and ANGPT2 then ob-
viously results in tumour angiogenesis and poor prognosis.
Therefore, an increased expression of ANGPT1 and
ANGPT2 in tumour tissue hints to an escalation of tumour
malignancy on the grounds of an altered vascularisation.
Ephrin B2 (EFNB2) is a member of the receptor
protein-tyrosin kinase family and is involved in many de-
velopmental processes; all members of the ephrin-B family
are transmembrane proteins. First observations led to the
assumption that a stronger expression of EFNB2 is associ-
ated with an increased vascularisation and tumour growth
as observed in human colorectal cancer. Afterward closer
investigation, the newly formed vessels were found func-
tionally inadequate and tumour growth showed a marked
decrease [11]. Due to their critical position in the angio-
genic pathway, ephrins turned out as operative therapeutic
targets: intervention with selective EFNB2 antibodies re-
sulted in impaired HUVEC migration and maturation, al-
tered tube formation, and in reduced angiogenesis [12].
The aim of this investigation was to examine the ex-
pression of key regulators of the angiogenic and vasculo-
genic cascades in OSCC tumour samples, from the
stimulation via VEGF to the mature endothelial cells
marked by CD31. Crucial questions were: (i) Is there a
significant expression profile? (ii) Are the selected angio-
and vasculogenic markers expressed? (iii) Does an altered
expression correlate firstly with an immunohistochemicaldetection of the protein, and secondly with clinical param-
eters such as survival, metastasis or recurrent disease?
Material and methods
Patient data
For this retrospective analysis, 83 tissue samples were
taken during tumour surgery after informed consent of
the patients in the years 2009–2012. Included were pa-
tients with a histological diagnosed squamous cell car-
cinoma of the oral cavity. These patients were over
18 years old and had not received any adjuvant radiation
or chemotherapy. Patients with recurrent disease were
included.
Healthy tissue controls (n = 30) were taken from oral
vestibular mucosa samples during orthognathic or trau-
matologic surgery after informed consent. The tissue
samples were snap-frozen in liquid nitrogen after sur-
gery and stored at −80 °C until further usage. The Ethics
Committee of the medical faculty approved the study
setup; the ID of the ethical clearance (WWU Muenster)
is 2008-580-f-s, and the study is registered in a public
Clinical Trials Registry, DRKS00000199.
RNA extraction and microarray assay
Total RNA was prepared by Qiazol extraction and puri-
fication with the miRNeasy Mini Kit (Qiagen). Purity
and integrity of the isolated total RNA was assessed on
the Agilent 2100 bioanalyzer (Agilent Technologies). For
microarray analysis, we used the Agilent Array platform
employing the manufacturer’s standard protocols for
sample preparation and microarray hybridization. Gene
expression analysis was performed with the Whole
Human Gene Expression Microarray (4x44K; GPL4133;
Agilent Technologies). After the washing steps arrays
were scanned using the Agilent G2505B Microarray
Scanner (Agilent Technologies) and feature extraction
was performed with Feature Extraction software version
9.5 (Agilent Technologies). Data files from mRNA mi-
croarrays were analysed by GeneSpring GX 7.3.1 accord-
ing to manufacturer’s protocol (Agilent Technologies).
The first normalisation step consisted of background
elimination while in a second step the 50th percentile of
each spot was normalized. Normalisation to healthy oral
mucosa pool was performed in the last step with the ex-
pression factor for the healthy oral mucosa pool set to 1.
Primary statistical analysis was performed with Gene-
Spring GX 7.3.1 software.
Immunohistochemistry
A selection of 14 paraffin embedded tumours samples
providing a representative amount of tissue for immuno-
histochemical staining was analysed in this investigation.
IHC was performed after histopathological confirmation
of OSCC. After examination only 14 of the 83 tissue
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decent analysis, these were included in the study.
Primary antibodies applied in this work: VEGF Ab-3
(clone JH12; NeoMarkers, Germany), CD31/PECAM1
(clone JC70A; dilution 1:20; Dako, Germany), Ephrin B2
(Abcam, United Kingdom), Angiopoietin 1 (clone N-18)
and Angiopoietin 2 (clone F-1; Santa Cruz, CA, USA).
The immunohistochemical procedure was performed
with the Dako REAL™ Detection Kit for VEGF Ab-3 and
the Dako LSAB™+ System-AP for Ephrin B2, Angiopoie-
tin 1, and 2 according to the manufacturer’s protocols
(Dako, Germany). For primary antibody detection of
CD31, the Dako EnVision™ + System- HRP was used in
combination with the Dako AEC+ High Sensitivity Sub-
strate Chromogen (Dako, Germany) according to the
manufacturer’s protocols.
Negative as well as positive controls were imple-
mented according to manufacturer’s protocols. Staining
results were summarized in an immunoreactive score
(IRS) based on the multiplication of percentage of posi-
tive cells (PP) and staining intensity (SI) ranging from 0
to 12. Definition of PP score: PP = 0 no staining, PP = 1
staining in less than 10 % of cells, PP = 2 staining in 10
to 50 % of cells, PP = 3 staining in 50 to 80 % of cells,
and PP = 4 staining in more than 80 % of cells. Defin-
ition of SI score: SI = 1 no staining, SI = 2 weak staining,
SI = 3 moderate staining, and SI = strong staining.Statistical analysis
Statistical analysis of expression factors and IRS score
according to tumour size, UICC stages and grading was
carried out by one way ANOVA using a modified Levene
testing and p < 0.05, and a PostHoc analysis with
Bonferroni-Holm testing (Daniel’s XL Toolbox version
6.53; http://xltoolbox.sourceforge.net).Results
Patient data
Tissue samples of 83 patients were analysed. Patients
age ranged from 31 to 92 years with a mean age of
63 years (±10 years); 11 patients were below 50 years.Table 1 Clinicopathological features of included OSCC samples
Localisation TMN
Number (%) T Number (%) N
Mouth floor 23 (27.7) T1 + T2 56 (67) N-
Alveolar ridge 22 (25.4) T3+ T4 27 (33) N+
Tongue 20 (24.0)
Buccal plain 8 (9.6)
Lip 5 (6.0)
Palate 3 (3.6)69 % of patients were male. Table 1 gives an overview of
localisation and grade of the OSCC samples.
Microarray analysis
Tissue samples used in microarray analysis were com-
posed to 100 % of malignant epithelial cells which was
affirmed by a pathologist. The exclusive presence of epi-
thelial cells was also ensured for the control tissue. Ex-
pression factors for the candidate genes were analysed
according to small and larger tumours (Table 2), to the
Union internationale contre le cancer (UICC) classifica-
tion (Table 3), and to grading (Table 4). Subsequently, one
way ANOVA was accomplished and differences in expres-
sion were analysed on a level of significance of p < 0.05.
EFNB2, ANGPT2, and VEGF were overexpressed in
84 % to 98 % of the tumour samples with an average ex-
pression factor of 2.3 to 4.5 (Table 2). Expression factors
of these genes increase with tumour size and grading
(Tables 2 and 4). In subdivision of the UICC classifica-
tion similar results could be observed, with an unantici-
pated shift in classification III (Table 3).
In contrast, PECAM1/CD31 and ANGPT1 were found
downregulated in 80 % to 95 % of tumour samples with
an average expression factor of 0.64 and 0.4, respectively.
The expression of PECAM1/CD31 correlated negatively
with tumour size and grading (Tables 1 and 3). A similar
expression pattern was observed with regard to ANGPT1.
In G1 tumours, the expression rate corresponded to
healthy mucosa samples. In G2 and G3, a decrease in the
expression rate from 1.13 to 0.28 was observed in 95 to
100 % of samples (Table 4). In UICC classification II–IV
expression factors of PECAM1 and ANGPT1 remained
constant (Table 3).
VEGF and EFNB2 showed a contrary gene expression
in small and larger tumours with lymphatic spread. The
expression increase in smaller tumours and decrease in
larger tumours in contrast to tumours without lymphatic
spread (Table 2). Gene expression of ANGPT2 showed
no variance in smaller tumours with and without lymph-
atic spread.
In contrast, in poorly differentiated tumours a higher
gene expression of VEGF, EFNB2 and ANGPT2 wasNumber (%) G Number (%) UICC Number (%)
53 (64) G1 2 (2.4) I 15 (18)
30 (36) G2 67 (80.7) II 22 (27)
G3 14 (16.9) III 9 (11)
IV 37 (44)
Table 2 Expression factors of angiogenesis-related genes and IRS score related to T and N in OSCC samples
Gene/Protein T1 + T2 T3 + T4
all (n = 56) IRS score
(n = 10)
N- (n = 39) N+ (n = 17) all (n = 27) IRS score
(n = 4)
N- (n = 14) N+ (n = 13)
VEGF (NM_001025366) 4.13 ± 2.70 (53) 5.8 4.10 ± 2.40 (37) 4.91 ± 4.15 (16) 4.81 ± 2.32 (27) 7.0 5.32 ± 2.68 (14) 4.25 ± 1.72 (13)
PECAM1 (NM_000442) 0.76 ± 0.40 (41) 0 0.55 ± 0.20 (28) 0.58 ± 0.16 (13) 0.52 ± 0.18 (24) 0 0.49 ± 0.21 (13) 0.54 ± 0.14 (11)
EFNB2 (NM_004093) 2.24 ± 1.08 (46) 4.0 2.06 ± 0.90 (32) 2.56 ± 1.25 (14) 2.39 ± 1.12 (24) 5.5 2.4 0 ± 1.04 (13) 2.39 ± 1.22 (11)
ANGPT1 (NM_001146) 0.51 ± 0.32 (51) 1.2 0.41 ± 0.32 (35) 0.33 ± 0.20 (16) 0.29 ± 0.16 (27) 1.5 0.27 ± 0.15 (14) 0.33 ± 0.18 (13)
ANGPT2 (NM_001147) 3.43 ± 1.73 (52) 5.2 3.52 ± 1.73 (35) 3.51 ± 1.08 (17) 3.91 ± 1.92 (25) 5.8 4.40 ± 1.81 (13) 3.39 ± 1.99 (12)
Expression factors were experimentally determined in relation to a healthy oral mucosa pool with an expression factor of 1; displayed is the median; ± means
Standard deviation; number of tumour samples in groups are in brackets
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ately differentiated tumours, gene expression of VEGF
and ANGPT2 were higher in tumours without lymphatic
spread; only EBFNB2 showed here a higher gene expres-
sion (Table 4).
Expression ratio of ANGPT1 against ANGPT2 in
smaller and larger tumour is shown in Table 5. Subse-
quently, one way ANOVA was accomplished and differ-
ences in expression were analysed on a level of
significance of p < 0.05. The ratio was found to decrease
with tumour size whereas in tumours with lymphatic
spread the ratio remained stable.
Immunohistochemistry
Haematoxylin and eosin staining of tumour specimens
was employed to select samples for IHC. Figure 1 gives a
review of all staining results using one tumour sample.
Tables 2, 3 and 4 present the IRS with reference to clas-
sification. Data were subjected to one way ANOVA and
differences in expression were analysed on a level of sig-
nificance of p < 0.05. Despite the small number of samples,
IRS results were consistent, and validated microarray
results.
IHC analysis gave further support of the microarray
data: while PECAM1/CD 31 could furthermore not be
detected in the analysed samples, the inverse regulation
of ANGPT1 and ANGPT2 was also underlined on the
protein level. No correlation of gene expression patternTable 3 Expression factors of angiogenesis-related genes and IRS sc




VEGF (NM_001025366) 3.21 ± 1.70 (14) 5.0 4.73 ± 2.59 (22)
PECAM1 (NM_000442) 0.63 ± 0.18 (9) 0.0 0.48 ± 0.17 (18)
EFNB2 (NM_004093) 1.48 ± 0.48 (11) 0.5 2.22 ± 0.93 (22)
ANGPT1 (NM_001146) 0.47 ± 0.18 (12) 1.5 0.31 ± 0.19 (22)
ANGPT2 (NM_001147) 3.81 ± 2.42 (13) 6.5 3.28 ± 1.46 (21)
Expression factors were experimentally determined in relation to a healthy oral mu
Standard deviation; number of tumour samples in groups are in bracketsor immunohistochemical detection of VEGF with clin-
ical parameters as well as long time survival or recurrent
disease was noticed.
Discussion
The prognosis of patients suffering from OSCC has been
unalterably poor despite much scientific effort to im-
prove the therapy. Tumour-related neo-angiogenesis is
an important prerogative for tumour growth and spread;
in different tumour entities, e.g. colon carcinoma, anti-
angiogenic therapy has proven its effect. Therefore, in
this study, we examined the expression of key regulators
in the angiogenic and vasculogenic cascade in 83 OSCC
tumour samples as the overexpression of single factors
during the angiogenic cascade might provide novel
points of attack. Our data demonstrate in malignant
tumours a significantly higher expression of VEGF,
ANGPT2 and EFNB2 at both, gene and protein levels, in
malignant tumours when compared to normal oral mu-
cosa. ANGPT1 and PECAM1/CD31 were regulated re-
versely when compared to ANGPT2. This pattern can
be regarded as a characteristic alteration in comparison
to healthy tissue. These results are in accordance with
findings in the current literature, which describe on the
one hand in particular overexpression of ANGPT2 and
VEGF, and on the other hand their positive interaction.
Li et al. published in 2013 results that underlined the hy-
pothesis that ANGPT2 expression is closely correlatedore related to UICC in OSCC samples







6.4 2.89 ± 1.2 (8) 6.0 5.21 ± 3.3 (37) 7.3
0.0 0.48 ± 0.19 (7) 0.0 0.54 ± 0.17 (31) 0.0
6.0 1.60 ± 0.36 (7) 4.0 2.89 ± 1.48 (31) 7.3
1.2 0.33 ± 0.25 (9) 0.0 0.33 ± 0.17 (36) 2.0
4.0 2.96 ± 1.12 (9) 6.0 3.77 ± 1.69 (36) 5.7
cosa pool with an expression factor of 1; displayed is the median; ± means
Table 4 Expression factors of angiogenesis-related genes and IRS score related to G and N in OSCC samples
Gene/Protein G1 (n = 2) G2 (n = 67) G3 (n = 14)
all IRS score
(n = 2)
N- (n = 1) N+ (n = 1) all IRS score
(n = 9)
N- (n = 44) N+ (n = 23) all IRS score
(n = 3)
N- (n = 8) N+ (n = 6)
VEGF (NM_001025366) 4.99 ± 3.90 (2) 8 1.09 8.9 4.22 ± 2.46 (65) 5.8 4.64 ± 2.65 (43) 3.47 ± 1.81 (23) 5.62 ± 3.92 (14) 6 3.1 ± 1.25 (8) 8.29 ± 6.44 (6)
PECAM1 (NM_000442) 0.98 ± 0.11 (2) 0 0.87 1.09 0.57 ± 0.18 (54) 0 0.55 ± 0.18 (36) 0.59 ± 0.16 (18) 0.36 ± 0.15 (12) 0 0.24 ± 0.09 (5) 0.47 ± 0.09 (6)
EFNB2 (NM_004093) 1.08 ± 0.69 (2) 4 0.41 1.76 2.36 ± 0.66 (55) 6.7 2.17 ± 0.92 (38) 2.72 ± 1.66 (19) 2.69 ± 1.08 (12) 1.3 2.13 ± 0.9 (5) 3.16 ± 1.18 (6)
ANGPT1 (NM_001146) 1.13 ± 0.17 (2) 6 1.3 0.96 0.34 ± 0.19 (64) 0.7 0.33 ± 0.19 (41) 0.36 ± 0.19 (23) 0.28 ± 0.17 (14) 0 0.36 ± 0.25 (8) 0.2 ± 0.07 (6)
ANGPT2 (NM_001147) 2.55 ± 1.68 (2) 4.5 0.87 4.23 3.53 ± 1.65 (64) 5.9 3.86 ± 1.89 (41) 2.94 ± 1.20 (23) 3.39 ± 1.82 (13) 6.7 1.81 ± 0.45 (6) 5.25 ± 1.47 (6)















Table 5 Gene expression ratio of ANGPT1 to ANGPT2
Ratio T1 + T2 T3 + T4
Ang1/Ang2 all 0.23 ± 0.32 0.15 ± 0.17
Ang1/Ang2 (N-) 0.25 ± 0.37 0.08 ± 0.08
Ang1/Ang2 (N+) 0.16 ± 0.15 0.22 ± 0.18
Ratio in healthy pool 1.0; ± means Standard deviation
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were of reduced maturity and stability [9]. When analys-
ing the overall survival rate they found no correlation
between VEGF expression and 5-year survival; neverthe-
less, this association was discussed controversially in the
literature [9].
Further studies have indicated a strong correlation be-
tween lymphatic spreading and survival in HNSCC [13,
14]. Jang et al. showed a significant correlation between
tumour dimension and biology to lymph node metasta-
ses and survival in HNSCC [15]. Remarkable results
identified by our data were the 2.7- and 2.9- fold gene
expression level of VEGF and ANGPT2 in poorly differ-
entiated tumours with lymph node metastasis versus
those without. VEGF and the angiopoietins are described
as important actors in anti-angiogenic therapy attacking
the microenvironment of the respective tumour [16].
The corresponding expression pattern of VEGF and
ANGPT2 hints to a complementary promoting role of
both factors in tumour vascularisation even whenFig. 1 Immunohistochemical detection of CD31 (b), Vegf (c), Ephrin B2 (d),
sample (IHC, x200; HE staining (a))considering the fact that ANGPT2 has been previously
described as an anti-angiogenic mitogen and VEGF an-
tagonist [17]. These observations may provide a possible
explanation for the reduced effects of an anti-angiogenic
therapy in OSCC; therefore, an additional intervention
on the ANGPT2 level might provide a potential thera-
peutic approach to sensitize target cells to antivascular
therapy.
The role of angiopoietins in tumour angiogenesis and
progression is not finally defined. Whereas ANGPT2 sig-
nalling results in vessel destabilisation, ANGPT1 overex-
pression is supposed to induce vessel development and
maturation [18]. In an IHC investigation of 40 tumour
samples, Chien et al. concluded that a strong protein ex-
pression of ANGPT1 or ANGPT2 hints to a pronounced
biological aggressiveness of the tumour tissue [19]. In
our study, we observed no notable overexpression of
ANGPT1, neither on the protein nor on the gene level.
Thus, ANGPT1 that exerts its effect via Tie-2 signalling
seems to play a lower-ranking role as an angiogenic fac-
tor in the neo-vascularisation of this tumour entity. In
conclusion, the analysis of patient data led us to the
suggestion that the progressive lack of ANGPT1 from
G1 to G3 tumours comes with reduced vessel ripening
which is marked immunohistochemically by weak
CD31 staining.
Another striking result elucidated by our analysis of
OSCC tumours is the oppositional regulation ofAngiopoietin 1 (e) and Angiopoietin 2 (f) in a T4 NØ G2 OSCC tumour
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ture suggests that the Ang1/ Ang2 ratio can be inter-
preted as a prognostic factor on gene expression as well
as the protein level, whereby a lower ratio is associated
with poor prognosis. Li et al. analysed the co-
downregulation of ANGPT1 and ANGPT2 protein ex-
pression in over 60 tumour samples and concluded from
their results that the examined descend of the Ang1/
Ang2 ratio correlates with pronounced vascularisation
and poor prognosis [19]. In the presented data, a low
ANGPT1/ ANGPT2 expression ratio was observed espe-
cially on gene expression level in patients which were di-
agnosed with a larger tumour size. The ratio in patients
with a lymphatic spread stayed unaltered low, however.
Particularly in recurrent disease, protein expression of
angiopoietins has been scrutinized [20]. Therefore, we
conclude that deregulated angiopoietins expression can
be linked with a significantly more pronounced bio-
logical aggressiveness of the tumour tissue; in particular,
the expression of ANGPT1 was associated with lymph-
atic metastasis. Our findings support the hypothesis that
functional vascularity provides a crucial prerogative for
the systemic spread of tumour that requires angiopoietin
signalling as an initial spark. Hence, analysis of the
angiopoietin ratio might emerge as a convincing prog-
nostic factor as the consideration of individual tumour
biology could support to plan therapeutic options. It might
help to determine the extent of neck dissection or adju-
vant therapy. Moreover ANGPT2 seems to play an out-
standing role in the development of metastatic spread and
thus must be considered as a prospective therapeutic tar-
get for attacking progressive disease. Nevertheless, critical
questions remain in which point of the signalling cascade
the positive effects of a medical intervention outweigh the
risk of the induction of malignant transformation when
interfering with immune cell interaction [21–23].
EFNB2 seems to be a relevant mediator not only in
vessel differentiation but also in vascular sprouting; how-
ever, the molecular regulation and downstream signal-
ling as well as the potential role as therapeutic target
remain unclear so far. Our analysis here, demonstrated
that the upregulated transcriptional regulation of EFNB2
corresponded well with the detected overexpression of
VEGF and ANGPT2. Gene expression of EFNB2 corre-
lated with tumour size and tumour differentiation. Also
a stronger overexpression was observed in tumours with
lymphatic spread against those without. Respectively,
Abéngozar et al. were able to inhibit tumour growth as
well as angio- and lymphangiogenesis; through the appli-
cation of highly specific anti-Ephr B2 antibodies EFNB2
was identified as a highly effective antiangiogenic target
in a mouse model for the first time [12]. In this model,
antibody treatment led to impairment of endothelial
cells’ velocity and orientation permanently.Conclusion
By analysing 83 tumour samples of OSCC patients, we
present here a characteristic expression profile of angio-
genic markers that are deregulated on the genetic level.
Furthermore, in a subgroup of these markers we con-
firmed these results additionally on the protein level.
Two major findings of our investigation are on the one
hand the distinctive expression pattern of the angiogenic
mitogens and on the other hand the characteristic in-
versely correlated Ang1/ Ang2 expression ratio. Starting
point for future investigations would be the analysis of
vessel maturation in malignant tissue as well as the rele-
vance and reliability of the angiopoietin ratio as a predic-
tion factor of tumour progression and prognosis.
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